The New Paradigm of Treatment for the Headache Patient

The CME activities on this page are offered as part of The New Paradigm of Treatment for the Headache Patient virtual conference. Don’t miss additional content offered in each tab below. Click on the tabs and links to learn more.

Instructions for claiming credit:
Read the CME Information document for the conference content prior to watching the videos. The videos can be accessed directly from this website. To receive your CME certificate or your certificate of participation, click the Claim Credit button below. You will be required to log in or create an account on MedEd Manager in order to complete the evaluation and posttest. Your certificate will be available to print or download immediately after completion.


Migraine Update – How New Treatment Options are Changing Patients’ Lives

Presenter: Merle L. Diamond MD
CME Activity InformationClaim Credit

New Preventive Therapies: Science and Mechanisms (MABS/Gepants)

Presenter: Stewart Tepper, MD
CME Activity InformationClaim Credit

Preventative Treatment: How Do We Integrate New Treatments and What Are Outcomes

Presenter: Robert Kaniecki, MD
CME Activity InformationClaim Credit

Acute Treatment: How Do We Integrate New Treatments and What Are Outcomes

Presenter: Jessica Ailani, MD
CME Activity InformationClaim Credit

Devices, Injections and Interventional Therapies Including OnabotulinumtoxinA

Presenter: Wade Cooper, DO
CME Activity InformationClaim Credit

Medication Overuse Headache: How Has the World Changed with the New Therapies

Presenter: Mark Green, MD
CME Activity InformationClaim Credit

An Integrated Treatment Approach Using Outpatient and Inpatient Services

Presenter: Merle Diamond, MD and Mark Greco, DPT
CME Activity InformationClaim Credit

Women and Migraine: Gender Based Approach and Treatment Options

Presenter: Jessica Ailani, MD
CME Activity InformationClaim Credit

Accessing Headache Care Through A Virtual Medicine Platform

Presenter: Konrad Kothmann, BS
CME Activity InformationClaim Credit

Cluster Headaches, TAC and Other Less Common Headache Types

Presenter: Vince Martin, MD
CME Activity InformationClaim Credit

Round Table Discussion: How Have the New Therapies Changes Your General Approach To Treating Patients In Your Practice?

Presenter: Jessica Ailani, MD; Wade Cooper, DO; Stewart Tepper, MD
CME Activity InformationClaim Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Forefront Collaborative and the Diamond Headache Clinic Research & Educational Foundation.
Forefront Collaborative is accredited by the ACCME to provide continuing medical education for physicians

Atogepant Significantly Reduces Mean Monthly Migraine Days In The Phase 3 Trial (Advance) For The Prevention Of Migraine

Presenters:Jelena M. Pavlovic, MD, PhD,1 David W. Dodick, MD,2 Deborah Friedman, MD, MPH,3 Stewart Tepper, MD,4 Lawrence C. Newman, MD,5 Richard B. Lipton, MD,1 Elyse G. Stock, MD,6 Alexandra Thiry, PhD,6 Charles M. Conway, PhD,6 Christopher M. Jensen, PharmD,6 Beth Morris, BA,6 Vladimir Coric, MD,6 Robert Croop, MD6

Objective: To compare rimegepant with placebo in the acute treatment of migraine for pain relief and ability to function normally at early (≤2 hours) and sustained (up to 48 hours) […]

Download Poster View Abstract

Real-World Evidence For Control Of Chronic Migraine In Patients Meeting American Headache Society Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added To Onabotulinumtoxina

Presenters:Andrew M. Blumenfeld, MD,1 Benjamin M. Frishberg, MD,1 Jack D. Schim, MD,1 Olivia Hughes, MS,2 Aubrey Manack Adams, PhD3

Objective: Combining onabotulinumtoxinA with CGRPmAbs can potentially be more effective than each therapy alone for preventing chronic migraine (CM). In the primary analysis cohort, records from 257 adults with CM […]

Download Poster View Abstract

Ubrogepant Is Effective In The Acute Treatment Of Migraine With Mild Pain

Presenters:Richard B. Lipton, MD,1 David W. Dodick, MD,2 Peter J. Goadsby, MD, PhD, DSc,3 Rami Burstein, PhD,4 Aubrey M. Adams, PhD,5 Hongxin Lai, PhD,6 Sung Yun Yu, BA,6 Michelle Finnegan, MPH,6 Joel M. Trugman, PhD6

Objective: Ubrogepant, approved for the acute treatment of migraine, demonstrated efficacy in treating migraine with moderate/severe pain. Clinical guidance recommends treatment when pain is mild, a strategy studied here for […]

Download Poster View Abstract

Sustained Efficacy And Safety Of Erenumab In Episodic Migraine Patients Failing 2–4 Prior Preventive Treatments: 2-Year Interim Results Of The Liberty Open-Label Extension Study

Presenters:Uwe Reuter, MD, PhD,1 Peter J. Goadsby, MD, PhD,2 Michel Lanteri-Minet, MD, PhD,3,4 Tracy Stites, PhD,5 Shihua Wen, PhD,5 Nadia Tenenbaum, MD,5 Michel D. Ferrari, MD, PhD,6 Shaloo Pandhi, MD,7

Affiliations: 1. Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 2. NIHR-Wellcome Trust, King’s Clinical Research Facility, King’s College London, London, UK; and Department of Neurology, University of California, Los […]

Download Poster View Abstract

Rimegepant 75 Mg Provides Early And Sustained Relief Of Migraine With A Single Oral Dose: Results From 3 Phase 3 Clinical Trials

Presenters:Jelena M. Pavlovic, MD, PhD,1 David W. Dodick, MD,2 Deborah Friedman, MD, MPH,3 Stewart Tepper, MD,4 Lawrence C. Newman, MD,5 Richard B. Lipton, MD,1 Elyse G. Stock, MD,6 Alexandra Thiry, PhD,6 Charles M. Conway, PhD,6 Christopher M. Jensen, PharmD,6 Beth Morris, BA,6 Vladimir Coric, MD,6 Robert Croop, MD6

Affiliations: 1. Albert Einstein College of Medicine, Bronx, NY USA; 2. Mayo Clinic Arizona, Scottsdale, AZ, USA; 3. University of Texas Southwestern Medical Center, Dallas, TX, USA; 4. Geisel School […]

Download Poster View Abstract


REN for the Acute Treatment of Migraine
Two esteemed headache experts, Dr. Andrew Blumenfeld & Dr. Brian Grosberg, discuss the latest advances in migraine treatment with a focus on REN & Nerivio.
Watch Now


Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.
Enter Lilly’s Headache Disorder Portfolio
Emgality MOA Migraine
Reyvow MOA


AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

Allergan, an AbbVie company

Allergan, an AbbVie company (NYSE: ABBV), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at


Biohaven Pharmaceuticals understands that migraine is more than a headache & is dedicated to advancing innovative therapies for acute & preventive treatment of this debilitating disease. As a patient-first company, Biohaven helps people with migraine & other neurological diseases who often have limited treatment options, live better, more productive lives.
Why Nurtec 
How to get Nurtec


Lundbeck, a global biopharmaceutical company, is tirelessly dedicated to restoring brain health, so every person can be their best. For more information, visit

Ajovy—a preventative treatment of migraine in adults

Access the clinical profile, key features, and more in the links below. IMPORTANT SAFETY INFORMATION Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Please see Prescribing Info below and more safety info at
Download the Brochure for AJOVY
Download the full Prescribing Information


Theranica develops non-invasive, drug-free, personalized wearable therapeutic products for the treatment of pain by integrating the latest neuroscience research with notable technological expertise.
Please take a tour of the Theranica Virtual Booth

Zomig Nasal Spray

Learn more about this prescription treatment option.
Product Website

National Headache Foundation

Founded in 1970, the National Headache Foundation (NHF) is the oldest and largest foundation serving individuals living with migraine disease and headache disorders. The NHF is the premier educational and informational resource for those in the headache community, health care professionals, and the public.
Check out NHF’s Added Qualification in Headache Medicine
Check out NHF’s Education and Informational Resources

Upsher-Smith Laboratories, LLC

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company striving to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. For more information, visit
Zembrace SymTouch (sumatriptan injection) 3 mg
Tosymra (sumatriptan nasal spray) 10 mg

Additional CME Courses

Select a course to start learning.

PPA CME Course

The 34th Annual Practicing Physician’s Approach to the Difficult Headache Patient

Update in Headache CME

2020 Update in Headache

Free Online CME

Explore More Free CME